B8FK — Biofrontera AG Income Statement
0.000.00%
- €14.28m
- €11.72m
- €21.67m
Annual income statement for Biofrontera AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 30.3 | 28.8 | 25.7 | 32.2 | 21.7 |
Cost of Revenue | |||||
Gross Profit | 26.8 | 24.9 | 21 | 26 | 16.3 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 38 | 4.13 | 24.6 | 27.1 | 27.1 |
Operating Profit | -7.61 | 24.7 | 1.12 | 5.13 | -5.47 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -12.7 | 35.7 | -43.2 | -2.13 | -6.72 |
Provision for Income Taxes | |||||
Net Income After Taxes | -13 | 33.9 | -44.2 | -0.369 | -4.35 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -13 | 38.3 | -44.2 | -0.369 | -4.35 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -13 | 38.3 | -44.2 | -0.369 | -4.35 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.8 | 2.57 | -9.37 | -0.071 | -0.716 |
Dividends per Share |